Literature DB >> 11841823

Component-specific surface and physiological activity in bovine-derived lung surfactants.

Robert H Notter1, Z Wang, E A Egan, B A Holm.   

Abstract

Composition, surface activity and effects on pressure-volume (P-V) mechanics are examined for lavaged calf lung surfactant (LS) and the clinical exogenous surfactants Infasurf and Survanta. Lavaged LS and Infasurf had closely-matching compositions of phospholipids and neutral lipids. Survanta had higher levels of free fatty acids and triglycerides consistent with its content of added synthetic palmitic acid and tripalmitin. Infasurf and Survanta both contained less total protein than LS because of extraction with hydrophobic solvents, but the total protein content relative to phospholipid in Survanta was about 45% lower than in Infasurf. This difference was primarily due to surfactant protein (SP)-B, which was present by ELISA at a mean weight percent relative to phospholipid of 1.04% in LS, 0.90% in Infasurf, and 0.044% in Survanta. Studies on component fractions separated by gel permeation chromatography showed that SP-B was a major contributor to the adsorption, dynamic surface activity, and P-V mechanical effects of Infasurf, which approached whole LS in magnitude. Survanta had lower adsorption, higher minimum surface tension, and a smaller effect on surfactant-deficient P-V mechanics consistent with minimal contributions from SP-B. Addition of 0.05% by weight of purified bovine SP-B to Survanta did not improve surface or physiological activity, but added 0.7% SP-B improved adsorption, dynamic surface tension lowering, and P-V activity to levels similar to Infasurf. The SP-B content of lung surfactants appears to be a crucial factor in their surface activity and efficacy in improving surfactant-deficient pulmonary P-V mechanics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11841823     DOI: 10.1016/s0009-3084(01)00197-9

Source DB:  PubMed          Journal:  Chem Phys Lipids        ISSN: 0009-3084            Impact factor:   3.329


  25 in total

1.  Surface film formation in vitro by infant and therapeutic surfactants: role of surfactant protein B.

Authors:  Olivier Danhaive; Cheryl Chapin; Hart Horneman; Paola E Cogo; Philip L Ballard
Journal:  Pediatr Res       Date:  2014-10-31       Impact factor: 3.756

2.  Synthesis and activity of a novel diether phosphonoglycerol in phospholipase-resistant synthetic lipid:peptide lung surfactants().

Authors:  Adrian L Schwan; Suneel P Singh; Jason A Davy; Alan J Waring; Larry M Gordon; Frans J Walther; Zhengdong Wang; Robert H Notter
Journal:  Medchemcomm       Date:  2011-10-19       Impact factor: 3.597

3.  Lucinactant attenuates pulmonary inflammatory response, preserves lung structure, and improves physiologic outcomes in a preterm lamb model of RDS.

Authors:  Marla R Wolfson; Jichuan Wu; Terrence L Hubert; Timothy J Gregory; Jan Mazela; Thomas H Shaffer
Journal:  Pediatr Res       Date:  2012-07-20       Impact factor: 3.756

4.  The role of natural processes and surface energy of inhaled engineered nanoparticles on aggregation and corona formation.

Authors:  Akira Tsuda; Nagarjun Konduru Venkata
Journal:  NanoImpact       Date:  2016-06-11

5.  Surfactant protein B inhibits secretory phospholipase A2 hydrolysis of surfactant phospholipids.

Authors:  R Duncan Hite; Bonnie L Grier; B Moseley Waite; Ruud A Veldhuizen; Fred Possmayer; Li-Juan Yao; Michael C Seeds
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-10-28       Impact factor: 5.464

6.  Adverse biophysical effects of hydroxyapatite nanoparticles on natural pulmonary surfactant.

Authors:  Qihui Fan; Yi E Wang; Xinxin Zhao; Joachim S C Loo; Yi Y Zuo
Journal:  ACS Nano       Date:  2011-07-20       Impact factor: 15.881

Review 7.  Surfactant therapy for acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; D Willson; R H Notter
Journal:  Crit Care Clin       Date:  2011-07       Impact factor: 3.598

8.  Functional importance of the NH2-terminal insertion sequence of lung surfactant protein B.

Authors:  Shelli L Frey; Luka Pocivavsek; Alan J Waring; Frans J Walther; Jose M Hernandez-Juviel; Piotr Ruchala; Ka Yee C Lee
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-12-18       Impact factor: 5.464

9.  Transcriptional responses of Mycobacterium tuberculosis to lung surfactant.

Authors:  Ute Schwab; Kyle H Rohde; Zhengdong Wang; Patricia R Chess; Robert H Notter; David G Russell
Journal:  Microb Pathog       Date:  2009-01-14       Impact factor: 3.738

Review 10.  Pharmacotherapy of acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; Gloria S Pryhuber; Patricia R Chess; Bruce A Davidson; Paul R Knight; Robert H Notter
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.